Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics-guided intravenous Busilvex conditioning for allogeneic transplantation in high-risk hematological malignancies
2014-000758-12Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Apr 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in acute myeloid leukemia (AML), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), multiple myeloma (MM) and 2 more, sponsored by Institut Paoli-Calmettes. Primary endpoint: Progression-free survival at 2 years. Started Apr 2014; status: completed.
02
Drugs
busulfan
03
Conditions
acute myeloid leukemia (AML)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)multiple myeloma (MM)acute lymphoblastic leukemia (ALL)cancer
Beyond the preview
Go deeper on 2014-000758-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000758-12.